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BACKGROUND Percutaneous coronary intervention (PCI) for unpro-
tected left main coronary artery (UPLMCA) using ﬁrst generation drug
eluting stents with ostial or mid-shaft lesions have favorable out-
comes. The safety and efﬁcacy of Xience V everolimus eluting stent
(EES) for this lesion subset is unknown.
METHODS The Xience V USA is an observational registry of 8000
patients who underwent PCI from 2008-2014, designed as a single
arm, non-randomized, post-approval study funded by Abbot Vascular.
We identiﬁed 83 patients who had PCI of a UPLMCA and compared
this to a matched cohort of 5275 patients who underwent PCI of a non-
UPLMCA lesion. The primary endpoint was the incidence of Academic
Research Consortium (ARC) deﬁned deﬁnite or probable stent
thrombosis (ST). The co-primary endpoint was a composite of cardiac
death and myocardial infarction (MI) at 1 year. The pre-speciﬁed
secondary endpoints included a composite of all cause death, MI,
repeat revascularization, target lesion failure (TLF) and major
bleeding complications. Follow-up was obtained up to 1 year and all
clinical endpoints were adjudicated by the Independent Clinical
Events Committee.
RESULTS Patients who underwent PCI of UPLMCA were older (>70
years of age, p¼0.0024), had more cardiovascular risk factors (dia-
betes mellitus 51.2% vs. 35.4%, p¼0.0036), established atherosclerotic
disease (multi-vessel coronary artery disease 53.0% vs. 24.0%,
p¼<0.0001) and renal insufﬁciency (20.7% vs. 9.9%, p¼0.0043).The UPLMCA cohort also had a lower mean EF (51.7% vs. 55.0%,
p¼0.0478). There were no differences in rates of deﬁnite or probable
stent thrombosis between UPLMCA cohort and non-UPLMCA cohort.
One year death and MI occurred in 7.6% of patients in the UPLMCA
cohort vs. 5.5% in the non-UPLMCA cohort (HR¼1.35 [0.60, 3.04],
p¼0.4611). In addition, there were no statistical signiﬁcant differences
in MACE event rates between the two groups (UPLMCA: 11.5 vs. 7.4%
non-UPLMCA, HR¼1.54 [0.79, 2.97], p¼0.1996). TLF was low at a rate
of 10.2% in the UPLMCA cohort versus 6.8% in the non- UPLMCA
cohort (HR¼1.48 [0.72, 2.98], p¼0.2721). Finally, TVR was performed
in 6.6% of patients with a UPLMCA cohort vs. 3% in the non-UPLMCA
cohort (HR¼2.21 [0.91, 5.38], p¼0.0738).
CONCLUSIONS When used in real world practice for UPLMCA PCI, the
Xience V EES is safe and effective with similar rates of stent throm-
bosis and low MACE event rates compared to non-UPLMCA PCI at one
year.
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BACKGROUND As progressively more elderly and comorbid patients
are being considered for revascularization the need for one year of
dual anti-platelets becomes of increasing concern. SYNERGY Ever-
olimus-eluting platinum chromium coronary stents allow for early
cessation of dual antiplatelet therapy (DAPT) due to complete polymer
absorption and drug elution by three months. The aim of this study
was to retrospectively assess those in our unit who have underwent
PCI with a SYNERGY stent to look for adverse outcomes post-
discontinuation of DAPT.
METHODS All patients in our unit who underwent clinically indicated
PCI with a SYNERGY stent from August 2013- December 2014 were
retrospectively analyzed. Patients who have been enrolled in multi-
center trails during the same time period are not included in this
cohort. Baseline and procedural characteristics were recorded.
Follow-up was by review of medical records or telephone contact for
post-procedural complications or adverse events.
RESULTS In total 100 patients underwent PCI with a SYNERGY
during the one-year study period. The mean age was 72.3 years
(10.0; range 41-92 years), 37% of the cohort was deﬁned as elderly
(age >75 years) and 8% deﬁned as very elderly (age >85 years). Mean
EuroSCORE was 11.37 (11.13, range 0.88-70.23). The indication for
SYNERGY stent use was as follows; frail or elderly (16%), concurrent
anticoagulation (28%) need for a non-cardiac procedure (10%),
increased bleeding risk (31%), or other (15%). NSTEMI/STEMI was the
presenting complaint in 32% of patients. The coronary disease was
complex. Left main stem was involved in (13%), multi-vessel disease
(36%), bifurcation disease requiring side-branch stenting (9%), and
37% required CTO intervention. Mean Syntax score was 22.7 (12.1,
range 6-53). The mean stent length/ patient was 75.3mm (41.5) with
1.44 0.64) lesions treated and 2.67 (1.33) stents implanted per pa-
tient. DAPT discontinuation by 3 months has occurred in 77% to date.
Despite the patient and lesion complexity, there were no thrombotic
events after discontinuation of anti-platelets (acute, sub-acute or late
stent thrombosis). Eleven patients were able to undergo non-cardiac
surgery after three months DAPT. By a minimum of six months (me-
dian follow up time per patient 341 days) follow up four patients died
from non-cardiac causes (one from cancer, one sepsis and multi-organ
failure, one ruptured abdominal aortic aneurysm and one vascular
complication post-TAVI). There were two target vessel re-
vascularizations (TVR) and one patient underwent CABG but no
incidence of stent thrombosis by the same time-point.
CONCLUSIONS The use of SYNERGY stents allows early discontin-
uation of DAPT, reducing the risk of bleeding complications and
facilitating non-cardiac procedures, without an increase in the inci-
dence of stent thrombosis. The results for TVR and clinical outcomes
are excellent for a complex patient and disease group.
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